About Scribe Therapeutics
Scribe Therapeutics is a company based in Alameda (United States) founded in 2018 by Jennifer A Doudna, Brett T Staahl, and David F Savage. Scribe Therapeutics has raised $120 million across 2 funding rounds from investors including T. Rowe Price, Orbimed and RA Capital. Scribe Therapeutics offers products and services including CRISPR-based Therapeutics and Epigenetic Long-Term X-Repressor Technology. Scribe Therapeutics operates in a competitive market with competitors including Beam Therapeutics, eGenesis, Korro Bio, Metagenomi and Prime Medicine, among others.
- Headquarter Alameda, United States
- Founders Jennifer A Doudna, Brett T Staahl, David F Savage
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$120 M (USD)
in 2 rounds
-
Latest Funding Round
$100 M (USD), Series B
Mar 17, 2021
-
Investors
T. Rowe Price
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Scribe Therapeutics
Scribe Therapeutics offers a comprehensive portfolio of products and services, including CRISPR-based Therapeutics and Epigenetic Long-Term X-Repressor Technology.
Engineers CRISPR systems for safe treatment of genetic diseases.
Develops technology for long-term genetic regulation in disease management.
People of Scribe Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Scribe Therapeutics
Scribe Therapeutics has successfully raised a total of $120M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $100 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Scribe Therapeutics
Scribe Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include T. Rowe Price, Orbimed and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on biotechnology startups
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
|
Locked | Locked | Locked |
Investor details for Scribe Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Scribe Therapeutics
Investment portfolio details for Scribe Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Scribe Therapeutics
Detailed financials for Scribe Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Scribe Therapeutics Comparisons
Peer comparison for Scribe Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Scribe Therapeutics
Scribe Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beam Therapeutics, eGenesis, Korro Bio, Metagenomi and Prime Medicine, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of gene therapy using CRISPR base editing to treat diseases
|
|
| Locked | Locked | Locked |
Gene transplantation platform for humanizing pig cells is developed.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
|
| Locked | Locked | Locked |
Next-generation gene editing tools are developed for drug enhancement.
|
|
| Locked | Locked | Locked |
Genetic therapies for diseases are developed using prime editing technology.
|
Detailed competitors of Scribe Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Scribe Therapeutics
Complete news archive for Scribe Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scribe Therapeutics
Scribe Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Scribe Therapeutics is headquartered in Alameda, United States. It is registered at Alameda, California, United States.
Scribe Therapeutics is a funded company, having raised a total of $120M across 2 funding rounds to date.
Founded in 2018 and headquartered in Alameda, United States, Scribe Therapeutics operates in the biotechnology sector. A proprietary X-editing (XE) platform, utilizing CRISPR technology and CasX enzymes with guide RNAs, is employed for in vivo genome modifications. Targeted genetic diseases include neurological and ophthalmological conditions, hematopoietic disorders, and applications in cell therapy. The platform enables precise gene knock-in or knock-out to address these health challenges.
Scribe Therapeutics's top competitors include eGenesis, Tessera Therapeutics and Korro Bio.
Scribe Therapeutics offers CRISPR-based Therapeutics and Epigenetic Long-Term X-Repressor Technology.
Scribe Therapeutics has 8 investors. Key investors include T. Rowe Price, Orbimed, RA Capital, Perceptive Advisors, and Avoro Capital Advisors.